Multifaceted roles of OCT4 in tumor microenvironment: biology and therapeutic implications
- PMID: 40229384
- DOI: 10.1038/s41388-025-03408-x
Multifaceted roles of OCT4 in tumor microenvironment: biology and therapeutic implications
Abstract
OCT4 (Octamer-binding transcription factor 4, encoded by the POU5F1 gene) is a master transcription factor for maintaining the self-renewal and pluripotency of pluripotent stem cells, as well as a pioneer factor regulating epigenetics-driven cell reprogramming and cell fate conversion. It is also detected in a variety of cancer tissues and particularly in a small subpopulation of cancer cells known as cancer stem cells (CSCs). Accumulating evidence has revealed that CSCs are a dynamic population, exhibiting shift between multipotency and differentiation states, or quiescence and proliferation states. Such cellular plasticity of CSCs is profoundly influenced by dynamic interplay between CSCs and the tumor microenvironment (TME). Here, we review recent evidence showing that OCT4 expressed in CSCs plays a multifaceted role in shaping the TME by interacting with the cellular TME components, including cancer-associated fibroblasts, tumor endothelial cells, tumor-infiltrating immune cells, as well as the non-cellular TME components, such as extracellular matrix (ECM), metabolites, soluble factors (e.g., growth factors, cytokines and chemokines), and intra-tumoral microbiota. Together, OCT4 regulates crucial processes encompassing ECM remodeling, epithelial-mesenchymal transition, metabolic reprogramming, angiogenesis, and immune responses. The complex and bidirectional interactions between OCT4-expressing CSCs and the TME create a supportive niche for tumor growth, invasion, and resistance to therapy. Better understanding OCT4's roles in such interactions can provide deeper insights into potential therapeutic strategies and targets for disrupting the supportive environment of tumors. The emerging therapies targeting OCT4 in CSCs might hold promise to resensitize therapeutic-resistant cancer cells, and to eradicate all cancer cells when combined with other therapies targeting the bulk of differentiated cancer cells as well as the TME.
© 2025. The Author(s), under exclusive licence to Springer Nature Limited.
Conflict of interest statement
Competing interests: The authors declare no competing interests.
Similar articles
-
Exosome crosstalk between cancer stem cells and tumor microenvironment: cancer progression and therapeutic strategies.Stem Cell Res Ther. 2024 Nov 22;15(1):449. doi: 10.1186/s13287-024-04061-z. Stem Cell Res Ther. 2024. PMID: 39578849 Free PMC article. Review.
-
Role of OCT4 in cancer stem-like cells and chemotherapy resistance.Biochim Biophys Acta Mol Basis Dis. 2020 Apr 1;1866(4):165432. doi: 10.1016/j.bbadis.2019.03.005. Epub 2019 Mar 21. Biochim Biophys Acta Mol Basis Dis. 2020. PMID: 30904611 Free PMC article. Review.
-
Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment.J Hematol Oncol. 2020 Oct 15;13(1):136. doi: 10.1186/s13045-020-00966-3. J Hematol Oncol. 2020. PMID: 33059744 Free PMC article. Review.
-
Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies.J Transl Med. 2023 Oct 2;21(1):686. doi: 10.1186/s12967-023-04575-9. J Transl Med. 2023. PMID: 37784157 Free PMC article. Review.
-
Drug Resistance Driven by Cancer Stem Cells and Their Niche.Int J Mol Sci. 2017 Dec 1;18(12):2574. doi: 10.3390/ijms18122574. Int J Mol Sci. 2017. PMID: 29194401 Free PMC article. Review.
Cited by
-
Harnessing the interaction between redox signaling and senescence to restrain tumor drug resistance.Front Cell Dev Biol. 2025 Jul 9;13:1639772. doi: 10.3389/fcell.2025.1639772. eCollection 2025. Front Cell Dev Biol. 2025. PMID: 40703657 Free PMC article. Review.
-
Integrated single-nuclei and spatial transcriptomic profiling of human sacrococcygeal teratomas reveals heterogeneity in cellular composition and X-chromosome inactivation.bioRxiv [Preprint]. 2025 Jul 24:2025.07.21.665156. doi: 10.1101/2025.07.21.665156. bioRxiv. 2025. PMID: 40777431 Free PMC article. Preprint.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical